Cargando…

FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer

BACKGROUND: The need to unfold the underlying mechanisms of lung cancer aggressiveness, the deadliest cancer in the world, is of prime importance. Because Fas-associated death domain protein (FADD) is the key adaptor molecule transmitting the apoptotic signal delivered by death receptors, we studied...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cimino, Y, Costes, A, Damotte, D, Validire, P, Mistou, S, Cagnard, N, Alifano, M, Régnard, J-F, Chiocchia, G, Sautès-Fridman, C, Tourneur, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388563/ https://www.ncbi.nlm.nih.gov/pubmed/22669160 http://dx.doi.org/10.1038/bjc.2012.196

Ejemplares similares

FADD adaptor in cancer
por: Tourneur, Léa, et al.
Publicado: (2005)

FADD phosphorylation is critical for cell cycle regulation in breast cancer cells
por: Matsuyoshi, S, et al.
Publicado: (2006)

The classical NLRP3 inflammasome controls FADD unconventional secretion through microvesicle shedding
por: Mouasni, Sara, et al.
Publicado: (2019)

Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness
por: Weiswald, L-B, et al.
Publicado: (2009)

New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer
por: Nisman, Benjamin, et al.
Publicado: (2016)

Osteopontin is a marker for cancer aggressiveness and patient survival
por: Weber, G F, et al.
Publicado: (2010)

Testosterone regulates cell proliferation in aggressive fibromatosis (desmoid tumour)
por: Hong, H, et al.
Publicado: (2011)

Epstein-Barr virus as a marker of biological aggressiveness in breast cancer
por: Mazouni, C, et al.
Publicado: (2011)

FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer
por: Baker, M J, et al.
Publicado: (2008)

Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis
por: Walsh, N, et al.
Publicado: (2010)

Low ANXA10 expression is associated with disease aggressiveness in bladder cancer
por: Munksgaard, P P, et al.
Publicado: (2011)

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype
por: Ameri, K, et al.
Publicado: (2010)

PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness
por: Molleví, D G, et al.
Publicado: (2008)

Elevated expression of myosin X in tumours contributes to breast cancer aggressiveness and metastasis
por: Cao, R, et al.
Publicado: (2014)

Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma
por: Siret, Carole, et al.
Publicado: (2018)

A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation
por: Weiswald, L-B, et al.
Publicado: (2013)

Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer
por: Wong, H, et al.
Publicado: (2010)

High expression of Lin28 is associated with tumour aggressiveness and poor prognosis of patients in oesophagus cancer
por: Hamano, R, et al.
Publicado: (2012)

Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response
por: Thoms, J W, et al.
Publicado: (2012)

The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer
por: Ragnum, H B, et al.
Publicado: (2015)

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error
por: Shipitsin, M, et al.
Publicado: (2014)

Absence of the DNA repair enzyme human 8-oxoguanine glycosylase is associated with an aggressive breast cancer phenotype
por: Karihtala, P, et al.
Publicado: (2012)

Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes
por: Lauvrak, S U, et al.
Publicado: (2013)

BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival
por: Hugdahl, Emilia, et al.
Publicado: (2016)

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma
por: Patard, J-J, et al.
Publicado: (2009)

Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation
por: Chugh, Seema, et al.
Publicado: (2016)

Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer
por: Nalwoga, H, et al.
Publicado: (2010)

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
por: Wang, L L, et al.
Publicado: (2015)

Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung
por: Robinson, Lary A, et al.
Publicado: (2016)

Interleukin-1α is the major alarmin of lung epithelial cells released during photodynamic therapy to induce inflammatory mediators in fibroblasts
por: Tracy, E C, et al.
Publicado: (2012)

A putative OTU domain-containing protein 1 deubiquitinating enzyme is differentially expressed in thyroid cancer and identifies less-aggressive tumours
por: Carneiro, A P, et al.
Publicado: (2014)

EIF5A2 predicts outcome in localised invasive bladder cancer and promotes bladder cancer cell aggressiveness in vitro and in vivo
por: Wei, J-H, et al.
Publicado: (2014)

Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease
por: Darby, S, et al.
Publicado: (2009)

A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours
por: Russell, Matthew R, et al.
Publicado: (2017)

Clinical significance of disseminated tumour cells in non-small cell lung cancer
por: Rud, A K, et al.
Publicado: (2013)

Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
por: Szpechcinski, A, et al.
Publicado: (2015)

Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer
por: Boldrini, L, et al.
Publicado: (2005)

A multi-analyte serum test for the detection of non-small cell lung cancer
por: Farlow, E C, et al.
Publicado: (2010)

Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients
por: Stovold, R, et al.
Publicado: (2013)

RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
por: Tsuta, K, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_559lmriospu3q4i0gp1mmsflis